Menu ×

HEALTHCARE & PHARMACEUTICAL

Polio Vaccine Market Segmentation By Product Type (Inactivated Poliovirus Vaccine or IPV [DTaP-HepB-Hib-IPV, DTaP-HepB-IPV, DTaP-Hib-IPV, DTaP-IPV, DT-IPV, and IPV] and Oral Poliovirus Vaccine or OPV [mOPV, Bivalent Oral Poliovirus Vaccine or bOPV and Trivalent Oral Poliovirus Vaccine or tOPV]); By Type (Single Drug and Combination Drug); By Distribution Channel (Offline and Online); and By End User (Public and Private Sectors)– Global Demand Analysis & Opportunity Outlook 2027

  • Text Size:

Introduction to Polio Vaccines

Poliovirus Vaccines or Polio Vaccines are a type of vaccines, which is used to prevent the disease caused by poliomyelitis. There are three serotypes of poliovirus, viz. type 1, type 2 and type 3. Depending upon the presence of different types of serotypes in different countries, different type of polio vaccines are used. Primarily, monovalent polio vaccines have antigen to response to one single type of poliovirus. Bivalent polio vaccines are responsive to type-1 and type-3 poliovirus, whereas, trivalent polio vaccines are responsive to all the three types of poliovirus.

Polio vaccines may often be used as a single drug or mixed with a combination of other drugs. Combined polio vaccine drugs are used for active immunization against diphtheria, tetanus, pertussis and infections caused by all known subtypes of hepatitis B virus and poliomyelitis. CLICK TO DOWNLOAD FREE SAMPLE REPORT

Polio Eradication

Market Size and Forecast

The global polio vaccines market is observing vibrant growth owing to rising awareness of poliovirus diseases and the growing need for vaccinating children among nations. Moreover, increasing investments for the development of different types of polio vaccines and rise in the number of annual dosage for polio vaccines around the globe is also expected to boost the growth of the global polio vaccine market.

The market is anticipated to record robust CAGR throughout the forecast period, i.e. 2019-2027. The global polio vaccine market is segmented by product type into inactivated poliovirus vaccine (IPV) and oral poliovirus vaccine (OPV), out of which, the oral poliovirus vaccine is anticipated to hold largest market share on account of growing utilization of the vaccine by various nations. The price of OPV as compared to IPV is very much less owing to the chemical composition of the vaccine, resulting in higher affordability and increasing purchase by lower and middle income economies. The WHO stated in one of its reports that purchase of OPV as per total annual dosage peaked 1,720,098,395 numbers from 11,489,000 numbers in-between 2013 and 2017.

Purchase of Poliovirus Vaccine

Polio Vaccine Market

Growth Drivers

Rising Awareness For Vaccination Against Poliomyelitis

Sudden outbreak of poliovirus disease in various countries is inducing the government of those nations as well as numerous world level organizations, such as World Health Organization (WHO) and The United Nations Children’s Fund (UNICEF), to raise awareness amongst the citizens in regards to poliomyelitis virus and the required vaccination processes. Owing to the fear of getting affected by the virus, people around the globe are immunizing their children with the vaccination processes.

GPEI And The Lowering Funding Activities

The WHO and the UNICEF and all the member nations have developed an initiative known as the Global Polio Eradication Initiative (GPEI), to eradicate poliovirus diseases globally, which is anticipated to raise the demand for polio vaccines globally for consumption by governmental organizations. Furthermore, significant reduction in funding activities have been observed gradually for GPEI, which is increasing the competition amongst private players in the polio vaccine market to expand their market share, especially in higher income economies. Owing to such factors, the market of global polio vaccine is anticipated to grow rapidly throughout the forecast period.

Restraints

Socio-Cultural Issues in Few Lower Income Nations

Few nations which belong to the lower income group, such as Pakistan and others, considers vaccination unimportant. Despite of regular trial processes for immunization in such areas, spread rumors, political issues and other social factors, all sums up to increased challenges for the operation of vaccination process. The overall planned budgetary purchase of vaccines are affected which is also leading to lowering sales of pharmaceutical companies.

Threat of Vaccine Contamination

At times, vaccines gets contaminated owing to genetic mutation, which causes the vaccine virus change it form to virulent itself. Unknowingly, if a child is vaccinated with such contaminated vaccine, the virus multiplies itself which might later be posing as a mass threat. All of these factors are anticipated to act as a barrier to the growth of the global polio vaccine market during the forecast period.

Market Segmentation

Our in-depth analysis of the global polio vaccine market includes the following segments:

By Product Type

  • Inactivated Poliovirus Vaccine
    • DTaP-HepB-Hib-IPV
    • DTaP-HepB-IPV
    • DTaP-Hib-IPV
    • DTaP-IPV
    • DT-IPV
    • IPV
  • Oral Poliovirus Vaccine
    • Monovalent Oral Poliovirus Vaccine (mOPV)
    • Bivalent Oral Poliovirus Vaccine (bOPV)
    • Trivalent Oral Poliovirus Vaccine (tOPV)

By Type

  • Single Drug
  • Combination drug

By Distribution Channel

  • Offline
  • Online

By End User

  • Public Sector
  • Private Sector

By Region

On the basis of regional analysis, the global polio vaccine market is segmented into five major regions including North America, Europe, Asia Pacific, Latin America and Middle East & Africa region.

Asia-Pacific is expected to have largest market share on the back of rising consumption of polio vaccines in the region. Moreover, increasing population in the region is raising the demand for immunization towards poliovirus by vaccinating new child births. Additionally, the region is surrounded by nations with lower and middle income groups, which is anticipated to raise the demand for oral polio vaccines, owing to lower price and subsidized availability. All of these factors are expected to support the growth of the market in the region. According to WHO vaccines purchase report, annual dosage of South East Asia region grew from 100,000 numbers in 2014 to 1,099,141,085 numbers in 2017.

Annual Dosage of Polio Virus Vaccine

The global polio vaccine market is further classified on the basis of region as follows:

  • North America (U.S. & Canada) Market size, Y-O-Y growth & Opportunity Analysis
  • Latin America (Brazil, Mexico, Argentina, Rest of Latin America) Market size, Y-O-Y growth & Opportunity Analysis
  • Europe (U.K., Germany, France, Italy, Spain, Hungary, Belgium, Netherlands & Luxembourg, NORDIC,  Poland, Turkey, Russia, Rest of Europe) Market size, Y-O-Y growth & Opportunity Analysis
  • Asia-Pacific (China, India, Japan, South Korea, Indonesia, Malaysia, Australia, New Zealand, Rest of Asia-Pacific) Market size, Y-O-Y growth & Opportunity Analysis.
  • Middle East and Africa (Israel, GCC (Saudi Arabia, UAE, Bahrain, Kuwait, Qatar, Oman), North Africa, South Africa, Rest of Middle East and Africa) Market size, Y-O-Y growth & Opportunity Analysis.

Top Featured Companies Dominating the Market

  • GlaxoSmithKline plc.
    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis
  • Sanofi Pasteur Limited
  • Astellas Pharma Inc.
  • Pfizer Inc.
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • Merck & Co., Inc.
  • Abbvie Inc.
  • Bharat Biotech
  • Serum Institute of India Pvt. Ltd.

Related Reports


Disclaimer | Privacy Policy | Terms & Conditions

Copyright © 2020 Research Nester. All Rights Reserved